Key Highlights

  • The fund tracks global healthcare companies spanning pharmaceuticals, biotechnology and medical devices.
  • Eli Lilly, Johnson & Johnson and AbbVie are the largest holdings by market value.
  • The portfolio includes 109 companies, with a 0.38 percent expense ratio.
  • Net Assets were about $4.7 billion on November 11, 2026.

The iShares Global Healthcare ETF (NYSEARCA:IXJ) closed at $114.86 on November 11, 2026, with net assets of about $4.7 billion. The fund seeks to track an index composed of global equities in the healthcare sector, offering access to pharmaceutical, biotech and medical device companies in several countries. Its portfolio reflects a mix of large drugmakers and diversified health companies based in North America, Europe and Asia.

Ticker and exchange

IXJ, NYSE Arca

Benchmark index

S&P Global 1200 Health Care (Sector) Capped Index (Net)

Net asset value

$114.79 (Nov 11, 2026)

Daily NAV change

Down $0.12 (-0.10%)

Net assets

$4,734,928,851

Number of holdings

109

Expense ratio

0.38%

30-day SEC yield

1.28%

Distribution frequency

Semi-annual

Fund inception

November 13, 2001

Global Healthcare Scope

The index behind IXJ covers large healthcare companies across developed markets, including the United States, Switzerland, the United Kingdom and Japan. Because drug pricing, Clinical Trials and regulatory approvals differ by country, the fund reflects a range of policy environments.

With 109 holdings, the portfolio gives wide coverage of the global healthcare sector. Pharmaceutical companies form a large part of the index, although biotechnology and medical equipment firms are also represented.

Largest Holdings

Eli Lilly accounts for about 11.53 percent of market value, followed by Johnson & Johnson at 6.81 percent and AbbVie at 5.23 percent. Merck holds roughly 4.04 percent, and UnitedHealth Group accounts for about 4.02 percent. Roche, Novartis, AstraZeneca, Thermo Fisher Scientific and Amgen also rank among the top ten.

The mix of Swiss, British and American drugmakers in the top positions shows how the global pharmaceutical sector is spread across regions. Large pharmaceutical companies account for most of the fund's weight.

Trading and Distribution Details

About 187,590 shares traded on November 11, 2026, compared with a 30-day Average Daily Volume of roughly 331,941 shares. The 30-day median bid-ask spread was 0.11 percent, and the fund had 41.25 million shares outstanding.

The fund distributes income semi-annually, and the June 2026 payment totaled $0.846056 per share. The 30-day SEC Yield was 1.28 percent and the 12-month trailing yield was also 1.28 percent, both calculated at the end of October 2026.

Final Word

IXJ provides global exposure to healthcare companies, with a 109-company portfolio anchored by large pharmaceutical firms. Its 0.38 percent expense ratio and semi-annual distributions set the cost and income structure. The fund's results will depend on Drug Development outcomes, pricing policies and the regulatory setting in each country where its companies operate.